Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lacutamab |
Synonyms | |
Therapy Description |
Lacutamab (IPH4102) is a monoclonal antibody that targets KIR3DL2, which potentially results in increased anti-tumor immune response against KIR3DL2-expressing tumor cells, and reduced tumor growth (PMID: 25361998, PMID: 31253572). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lacutamab | IPH-4102|IPH 4102|IPH4102 | Lacutamab (IPH4102) is a monoclonal antibody that targets KIR3DL2, which potentially results in increased anti-tumor immune response against KIR3DL2-expressing tumor cells, and reduced tumor growth (PMID: 25361998, PMID: 31253572). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03902184 | Phase II | Gemcitabine + Lacutamab + Oxaliplatin Lacutamab | IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) | Active, not recruiting | USA | POL | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT05321147 | Phase I | Lacutamab | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 | Completed | USA | 1 |